PillRx only · Injection, Solution · Subcutaneous
Hyaluronidase
Brands: Hylenex Recombinant · Hyaluronidase (Human Recombinant)
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US2 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$53.747
Latest avg · Jul 22, 2026
+1%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
267
Rx · 2026 Q1
307
Units dispensed
-49%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| HF Acquisition Co LLC, DBA HealthFirst | unknown | 1 | SUPPLYING |
| Antares Pharma, Inc. | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Sep 11, 2024RECALLRecall (Class II): Hylenex recombinant (hyaluronidase) injection, 150 USP units/mL, 4x1 mL Single Dose Vials, Rx only, Manufactured for an…
cGMP Deviations: Temperature excursion — Recalling firm: Mckesson Medical-Surgical Inc. Corporate Office — Virgina